RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors

Childhood cancer survivors, adolescent/young adults with no cancer history and newly diagnosed cancer patients

Inclusion Criteria:

Childhood Cancer Survivors

• Diagnosis of cancer at age 21 or younger
• Current age 16-40 years
• 1year and ≤ 15 years from end of cancer treatment
• Received ≥ 200 mg/m2of anthracycline (Doxorubicin equivalent doses, see Appendix VI; 200 mg/m2 of doxorubicin = epirubicin 300 mg/m2; daunorubicin 240 mg/m2; zorubicin 400 mg/m2; mitoxantrone 50 mg/m2; idarubicin 40 mg/m2.)
• Asymptomatic (Appendix VII: absence of palpitations, dyspnea, edema or anginal symptoms)
• No pre-existing diagnosis with regard to cardiovascular or cerebrovascular disease status.
• BMI ≤35.0

Adolescent/young adults with no cancer history

• No prior diagnosis of cancer, diabetes, or lung disease
• Current age 16-40 years
• No history of radiation to chest or neck
• No prior history of chemotherapy
• Asymptomatic (Appendix VII : absence of palpitations, dyspnea, edema or anginal symptoms) and without a pre-existing diagnosis with regard to cardiovascular or cerebrovascular disease status.
• BMI ≤35.0

Newly diagnosed cancer patients

• Diagnosis of cancer at age 25 or younger
• Current age 16-25 years
• Planned receipt of anthracycline chemotherapy ≥ 200 mg/m2 of anthracycline (Doxorubicin equivalent doses, see Appendix VII; 200 mg/m2 of doxorubicin = epirubicin 300 mg/m2; daunorubicin 240 mg/m2; zorubicin 400 mg/m2; mitoxantrone 50 mg/m2; idarubicin 40 mg/m2.)
• Planned treatment course ≤ 15 months
• No pre-existing cardiovascular disease
• BMI ≤35.0

Exclusion Criteria:

All groups

• Subjects with implanted electronic devices, including but not limited to: pacemakers, defibrillators, functioning neurostimulator devices, or other implanted electronic devices
• Subjects with ferromagnetic cerebral aneurysm clips, or other intraorbital/intracranial metal
• Claustrophobia
• Subjects who received total body irradiation or cranial irradiation
• History of acute myocardial infarction
• Significant ventricular arrhythmias (>20 PVC's/minute due to gating difficulty)
• Medical history of moderate or severe aortic stenosis, or other significant valvular disease
• Women who are pregnant
• Those with pre-existing history (by self report in Group B and review of medical records in addition to self-report for Groups A & C) of abnormal cardiovascular function including: congenital heart disease, hypertension, diabetes, hypercholesterolemia on treatment, a body mass index >35, history of asymptomatic cardiac dysfunction (defined as an ejection fraction < 40 and/or shortening fraction < 28) or symptomatic cardiac dysfunction (congestive heart failure), stroke, renal dysfunction by history/medical records (serum creatinine >1.4), anemia, obstructive or restrictive airways disease
• Asymptomatic cardiac dysfunction (defined as an ejection fraction < 40 and/or shortening fraction < 28 on last ECHO or MUGA)
• Participants unwilling to complete the protocol (1 visit for Group A, B; 3 scan studies for Group C)
• Participants unable to provide informed consent via a guardian or self